The phase 2 LixiPark trial (NCT03439943) showed that treatment with lixisenatide (Adlyxin, Sanofi), a glucagon-like peptide-1 receptor agonist used as a therapy for diabetes, may have resulted in less progression of motor disability compared with placebo at 12 months in patients with early Parkinson disease (Parkinson’s disease) but was associated with gastrointestinal adverse effects. The results of this recent trial add further evidence to exenatide’s potential as a drug that might slow the progression of Parkinson’s and pave the way for the larger phase III clinical trial that is currently underway;

Diabetes mellitus is a risk factor for Parkinson's disease. UK's Cure Parkinson’s has been at the forefront of exenatide’s journey as a potential treatment for Parkinson’s from the outset. They funded the first clinical study of exenatide in people with Parkinson’s. This was a year-long pilot study in 2008 involving 45 people with Parkinson’s. Those who took exenatide did not experience the decline in their movement that is normally seen due to Parkinson’s. Actually, these participants improved a little. Crucially, some of these benefits were still present when measured one year after the participants had stopped taking exenatide, giving hope that this medicine had interfered with the underlying disease process, rather than simply masking symptoms.

Liraglutide is another drug that belongs to a class of medicines called Glucagon-like peptide 1 (GLP-1) receptor agonists. In addition to treating T2 diabetes and obesity, this class of drugs has another interesting property: taming inflammation. In animal models of Parkinson’s, liraglutide has shown strong neuroprotective effects.

Based on this, Cure Parkinson’s in 2017 funded Professor Michele Tagliati to undertake a phase II randomized, double-blind, placebo-controlled clinical trial of liraglutide in people with Parkinson’s.

70 participants were given either once-daily injections of liraglutide or placebo injections for 52 weeks. The study was primarily designed to assess changes in symptoms whilst off Parkinson’s medication for 12 hours before the assessments. Movement (motor), non-motor, and cognitive symptoms were assessed along with several secondary measures, including quality of life and daily activities. The primary analysis of the results included 37 people with Parkinson’s on liraglutide and 18 on the placebo drug.

Non-motor symptoms, activities of daily living, and quality of life appeared to significantly improve in the group on liraglutide treatment. However, there was no clear difference in motor symptoms between those on liraglutide and those on the placebo; it was noted that there appeared to be a strong placebo effect in this study, meaning the participants, even though none was aware they were taking the placebo drug, believed they were experiencing therapeutic results. This is consistent with the often-reported association of more invasive treatments causing a stronger placebo effect.

The research team also reported a significant lowering of body mass index (BMI) and average blood glucose levels in the active drug group, which are not desirable for patients in general. Interestingly, significant mobility improvements were reported by people taking liraglutide in their quality of life experiences, and this was more than in the placebo group.

In this new phase II of lixisenatide trial, the effect of lixisenatide was assessed on the progression of motor disability in persons with Parkinson’s disease.

Participants with Parkinson’s disease who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary endpoint was the change from baseline in scores on the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary endpoints included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent.

A total of 156 patients 40 to 75 years old with early Parkinson’s disease (diagnosed less than 3 years earlier) on stable symptomatic medications without motor complications were randomized 1:1 (with 78 assigned to each group) to subcutaneous injections of 20 µg lixisenatide or placebo once daily for 12 months, followed by a 2-month washout period. Patients randomized to lixisenatide received 10 μg/day for 14 days and then 20 μg/day administered by once-daily subcutaneous injections for 12 months. If patients were unable to tolerate the dose of 20 μg/day, it would have been reduced to 10 μg/day. Patients were expected to remain on a stable dosage of antiparkinsonian medications for at least the first 6 months of the trial, and optimally for the entire 14 months of follow-up. An interesting feature of the trial was that the drug was tested both during ON and OFF levodopamine periods.

MDS-UPDRS scores at baseline were approximately 15 in both groups.

• At 12 months, scores on the MDS-UPDRS had changed by −0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group.

• At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary endpoints did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%.

What is lixisenatide?

Lixisenatide is a once-daily injectable GLP-1R agonist that is used in the treatment of Type 2 diabetes (brand name ‘Lyxumia’ in the EU and ‘Adlyxin’ in the USA). Lixisenatide can cross the blood-brain barrier.

What is a GLP-1R agonist?

Glucagon-like peptide 1 receptor agonists (or GLP-1R agonists) are a class of drugs used in the treatment of Type 2 diabetes. They act by mimicking the action of a naturally produced gut hormone called GLP-1 in the body. GLP-1 is produced by cells lining the intestines when food and drink is consumed, stimulating insulin to be released by the pancreas. Insulin helps cells absorb glucose from our food (sugar) to be used as energy.

The LixiPark study was led by Prof Olivier Rascol (University of Toulouse) and Prof Wassilios Meissner (University of Bordeaux). LixiPark is a multicenter trial performed at 21 centers of the French NS-Park/FCRIN network.

The study, sponsored by the Toulouse University Hospital, was co-funded by UK charity Cure Parkinson’s, with Van Andel Institute (VAI; in Michigan, US), and the French Ministry of Health, with drug and placebo support from pharmaceutical company Sanofi.

The LixiPark trial was a phase 2 clinical trial. Phase 2 studies often include measures of efficacy to get an idea of whether a treatment is doing what it is supposed to achieve. Phase 3 is the last stage of clinical testing and involves a very large cohort of people affected by the disease being tested for a long time to determine the effectiveness of the potential treatment alongside its long-term safety. A Phase III clinical trial of Lixisenatide in Parkinson's is ongoing.

What will happen next?

UK's Cure Parkinson’s is working with the investigators to plan the next phase of development of GLP-1R agonists for Parkinson’s. They are also awaiting the results of the phase 2 Stockholm study and the phase 3 UK trial of exenatide, another GLP-1R agonist, in Parkinson’s. These results are expected later this year and they will help to inform the next steps for this class of drugs.

Can Parkinson’s patients take lixisenatide? Lixisenatide is still considered to be experimental for use in Parkinson’s and more research is required. There are currently no GLP-1R agonists, including lixisenatide, that are approved for use in Parkinson’s. GLP-1R agonists are also currently considered an experimental class of drugs for Parkinson’s.

There is a wide range of subtle differences between the broader class of GLP-1R agonists and they have not all been tested in Parkinson’s. Some GLP-1R agonists significantly reduce body weight (which might add concerns of frailty for people with Parkinson’s). Some GLP-1R agonists do not cross the blood-brain barrier very well and therefore are not able to have an effect in the brains of people with Parkinson’s. It is important to note that more research is required to better understand these differences in the context of a potential treatment for Parkinson’s.

When are the results expected of the Phase III exenatide trial?

The study finishes in the first half of 2024, so it is hoped that the results will be available in the second half of 2024. Researchers are also waiting for the results of a large clinical trial examining the effects of a two-year course of exenatide in people with Parkinson’s disease.

“There is a number called the 'clinically meaningful threshold' and we should appreciate that the results 'fell short' of this important metric so it is not ready for prime time in patients. In my view we should not rush to prescribe this drug or to try to creatively acquire it for our patients. We have been down this road many times including leukemia drugs, cough syrups and lithium for Parkinson. The data is not yet there to proceed to prescribing,” Michael S. Okun, MD, national medical advisor for the Parkinson's Foundation, told NeurologyLive®. “More importantly, the weight loss associated with GLP-1’s is not desirable in the majority of cases of Parkinson disease and the nausea and vomiting will not be a welcome symptom. The drug and trial is a step in the right direction, though there is much work to do.”

Will effects last?

David Standaert, a neurologist at the University of Alabama at Birmingham, who was not involved in the trial, says it’s important to know whether the effect will last beyond a year.

“We’re all cautious. There’s a long history of trying different things in Parkinson’s that ultimately didn’t work,” he says. A difference of three points in the rating score is a small change, one that many people with Parkinson’s would struggle to notice. What happens at 5 years? Is it 15 points then, or is it still 3? If it’s still 3, then this is not worth it.” He said.

More questions

A bit astonishing is that apparently, French researchers did not record any imaging biomarkers in the study to monitor disease progression and changes with drug administration. Since the trial was conducted in France, data collection regarding race or ethnic group is prohibited by law. The authors only tested 1 dose of lixisenatide, and thus other doses might have better or worse effects in patients with Parkinson’s disease.

As GLP-1 is a naturally produced hormone in the gut, it would have been interesting to search for changes in microbiome. It is well known since Heiko Braak that alpha-synuclein propagation starts in the gut.

GLP-1 inhibitors are also known to reduce inflammation, was inflammation measured? It is not reported.

Among the authors, there were many consultants, who had worked for several pharmaceutical companies, including Abbvie, that has an interest in drugs for Parkinson's disease.

Recently I learned something new in anatomy (I am a noob in anatomy). It's known for some times there are mirror neurons, but there is an interesting subset: The mirror motor neurons. It was mentioned on a forum by a pALS (patient with ALS) who told he rehabilitated his bladder thanks to mirror motor neurons. Near my home in France, there is a center that uses similar techniques for people who unfortunately experienced strokes. Bladder issues are unfortunately common in ALS patients. These issues arise because ALS affects the nerve cells that control the muscles in bladder and sphincter.

This forum post picked my curiosity and I looked in Pubmed. Indeed there are many sudies that discuss about this kind of rehabilitation technique in ALS and Parkinson's disease. It's called Motor Imagery and there is even a Wikipedia about it.

If you pardon me for grave oversimplification, it's a matter of showing some action to the subject, for example someone is walking, and then asking to the subject to imagine doing the same thing.

The ALS patient told it needed years to regain control of his sphincter, so it's not possible to find some scientific litterature that would enlight us on the results wa can expect with this long duration of rehabilitation, without mentioning that unfortunately many ALS patients do not live that long. Scientists are usually busy people, their studies last between days and a few months as it must coincide with academic time. But there are many studies that mention that even after a few tests, a positive effect can be detected. Here is an example.

A review on Parkinson's disease is less optimistic, it tells of ~5% motor improvement.

I wonder to which extend this Motor Imagery could help to regain some important functionality. Maybe some reinforcement could be added when the imaging process is detected. Apparently even a simple EEG is able to detect this mental state. The article cited above has some additional details on this. It calls also in question why those mirror motor neurons are not striked by the disease as they are probably colocated with upper motor neurons.

Introduction

L'article (en pre-print) discuté aujourd'ui traite de nutrition et de la maladie de Parkinson. La maladie de Parkinson est le deuxième trouble neurodégénératif le plus répandu dans le monde et entraîne une réduction significative de la qualité de vie. Les tendances actuelles en matière d'incidence, de prévalence et de charge de morbidité montrent que le fardeau mondial de la maladie de Parkinson a augmenté.

Les connaissances actuelles suggèrent de façon très générales que la maladie de Parkinson est probablement causée par une interaction entre une prédisposition génétique et la présence de facteurs environnementaux qui peuvent s'accumuler tout au long de la vie, c'est à dire que les scientifiques ont de grandes difficultés à identifier les facteurs à risques. Même le diagnostic semble ne pas faire l'unanimité des chercheurs, pour certains le problème est le manque de production de dopamine dans une certaine zone du cerveau, pour d'autres il s'agit d'une maladie liée à l'accumulation d'une protéine mal-formée: L'alpha-synucléine.

Le fer a peut-être un rôle particulier dans la maladie de Parkinson car il est nécessaire à l'enzyme limitant la production de dopamine. En effet celle-ci, la tyrosine hydroxylase, catalyze la conversion de l'amino acide L-tyrosine vers le L-3,4-dihydroxyphenylalanine (L-DOPA). Pour cela elle a besoin d'oxygène et de fer et aussi de tetrahydrobiopterine comme cofactors. L-DOPA est un precurseur de la dopamine, qui à son tour est un precurseur des neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline). De même il existe une relation entre le métabolisme des glucides et celui du fer. Ce qui suggère qu'un métabolisme anormal des glucides puisse avoir une relation avec l'apparition de la maladie de Parkinson.

Les facteurs environnementaux qui se sont avérés liés au risque de maladie de Parkinson comprennent : * Les facteurs associés à un risque réduit de maladie de Parkinson sont le tabagisme, la consommation d'alcool, et la consommation de caféine. De façon moins claire on trouve aussi notamment la vitamine E, les flavinoïdes et le β-carotène ou encore la viande rouge. * Tandis que l'exposition aux pesticides ou aux herbicides et aux blessures à la tête1 sont associés à un risque accru de maladie de Parkinson. Il a également été suggéré que les produits laitiers pourraient augmenter le risque de maladie de Parkinson.

Il existe une relation bien établie entre le microbiome intestinal et la pathogenèse de la maladie de Parkinson. Certaines théories développées sur l'étiologie de la maladie de Parkinson, telles que l'hypothèse de Braak, affirment que la maladie de Parkinson peut commencer dans le système nerveux entérique de l'intestin avant de remonter jusqu'au cerveau. Ces théories sont étayées par des associations connues entre les problèmes gastro-intestinaux prodromiques et le biomarqueur caractéristique de la maladie de Parkinson, l'α-synucléine, dans le système nerveux entérique avant le diagnostic de la maladie de Parkinson.

Fer et maladie de Parkinson

Une accumulation accrue de fer dans des régions comme la substance noire et les noyaux gris centraux et une dyshoméostasie du métabolisme du fer sont des constatations courantes chez les patients parkinsoniens. Malgré cela, les recherches sur le fer alimentaire ont donné des résultats mitigés. Dans l’ensemble, l’apport alimentaire en fer ne semble pas être associé au risque de maladie de Parkinson, mais des analyses de sous-groupes dans les sous-populations occidentales et masculines ont révélé que, dans ces sous-groupes, le fer alimentaire était associé à une augmentation significative du risque de maladie de Parkinson.

Comme souvent, certaines études signalent que l'anémie est associée à un risque accru de maladie de Parkinson, tandis que d'autres rapportant le contraire. Ces résultats apparemment contradictoires peuvent suggérer une relation non linéaire dans lequel à la fois, des niveaux faibles et élevés de fer cérébral dans les circuits moteurs sont associés à un risque accru de maladie de Parkinson

Motivation

Bien que des travaux antérieurs aient étudié les habitudes alimentaires des patients atteints de maladie de Parkinson, cela ne fournit pas de compréhension mécaniste de la façon dont les différences alimentaires peuvent entraîner des profils de risque différentiels de maladie de Parkinson. Dans ce nouvel article, des chercheurs étudient les différences en matière de fer dans le cerveau liées aux facteurs alimentaires et liés au mode de vie liés au risque de maladie de Parkinson en utilisant un biomarqueur cérébral spécifique du fer de la maladie de Parkinson, qu'ils appellent PVS cérébral d'hémochromatose. Ce biomarqueur regroupe les signaux d'accumulation de fer provenant des IRM cérébrales T2-w des régions motrices, notamment le cervelet, le thalamus, le caudé et le putamen.

Les auteurs ont cherché à comprendre comment les facteurs alimentaires et ceux liés au mode de vie influence la présence de ce biomarqueur spécifique du fer et comment cela est lié au risque de maladie de Parkinson.

Leurs investigations montrent que les préférences alimentaires en faveur (bizarrement) de l'alcool et la consommation de produits frais sont associées à un risque réduit de maladie de Parkinson, et que l'apport alimentaire et les préférences en faveur des aliments sucrés sont associés à un risque accru de maladie de Parkinson.

Il semblerait qu'une relation existe dans laquelle les nutriments et les préférences alimentaires liés à des niveaux de fer cérébraux plus faibles seraient associés à un risque accru de maladie de Parkinson.

La dérégulation du fer est une caractéristique courante du maladie de Parkinson, et des essais cliniques de la chélation sont en cours comme voie de traitement potentielle pour le maladie de Parkinson et d'autres maladies neurodégénératives.

Par exemple les essais cliniques concernant le défériprone comme traitement de la neurodégénérescence associée à la pantothénate kinase, une maladie génétique liée à une accumulation accrue de fer dans le cerveau et à des symptômes liés au mouvement. Mais ces essais cliniques ont montré que le défériprone n'entraînait qu'une réduction très faible de la progression de la maladie.

Les essais sur la défériprone, un chélateur du fer, pour le traitement de la maladie de Parkinson ont donné des résultats mitigés. La aussi les essais ont montré une réduction de l'accumulation de fer dans certaines zones du cerveau, mais aucune amélioration significative des symptômes.

Sucres et glucides

Dans toutes leurs analyses, les scientifiques ont constaté que les facteurs liés aux glucides dans les préférences et l'apport nutritionnel estimé étaient associés à une diminution du PVS cérébral de l'hémochromatose, à une augmentation du risque de maladie de Parkinson.

La littérature suggère un effet bidirectionnel avec : * a) un taux élevé de fer influençant la régulation glycémique et augmentant le risque de diabète de type II, une maladie principalement causée par une altération aiguë de la régulation glycémique, * b) l'ingestion orale de glucose entraînant des modifications des facteurs du métabolisme du fer résultant en fer périphérique.

Le fer peut jouer un rôle dans le développement de la résistance à l’insuline. La littérature scientifique à ce jour, montre que la dérégulation glycémique et les maladies associées sont liées à un risque accru de maladie de Parkinson et à de pires résultats de la maladie de Parkinson.

Un métabolisme dérégulé du fer pourrait conduire à des envies inadaptées de glucides, ce qui pourrait déréguler conjointement le métabolisme du glucose et du fer, conduisant à une boucle de rétroaction. La dérégulation fragmentée du métabolisme du fer et du glucose peut expliquer pourquoi une manifestation occasionnelle de carence en fer comme le pika, incite à manger des aliments riches en glucides comme l'amidon, le riz non cuit et les pâtes non cuites.

Les sucres et les glucides peuvent également avoir un impact sur le risque de maladie de Parkinson et l’accumulation de fer au niveau du microbiome. Une forte préférence alimentaire pour les sucreries et les glucides peut augmenter les niveaux de bactéries pathogènes opportunistes pro-inflammatoires dans l’intestin, ce qui est fortement lié à un risque accru de maladie de Parkinson. Ce modèle alimentaire est également en corrélation avec la pathologie de la ɑ-synucléine, qui peut émerger d’un état intestinal dysbiotique et pro-inflammatoire.

Alcool

Il existe également une littérature importante selon laquelle la consommation d’alcool a un impact sur l’absorption et l’accumulation du fer. L’alcool peut entraîner une accumulation accrue de fer dans le cerveau82. L’alcool est connu pour réguler négativement la synthèse de l’hepcidine, une hormone régulatrice du fer, et, en cas de consommation excessive, peut provoquer une surcharge en fer chez des individus par ailleurs hémodynamiquement typiques. En particulier chez les personnes atteintes d’hémochromatose héréditaire, la consommation d’alcool est largement associée à de pires résultats en matière de santé. Des effets similaires sont observés dans d’autres troubles de surcharge en fer comme la bêta-thalasémie.

Exercice physique

Les auteurs ont constaté que les préférences liées à l'exercice sont associées de manière significative à une réduction du risque de maladie de Parkinson et à une réduction du fer cérébral, telles que mesurées avec le PVS cérébral de l'hémochromatose. Evidemment les principaux déficits moteurs de la maladie de Parkinson rendent l'activité physique moins attractive. Mais des niveaux d’activité modérés à élevés se sont avérés associés à un risque plus faible de développer une maladie de Parkinson plus tard dans la vie et les personnes atteintes de maladie de Parkinson qui déclarent une activité physique plus élevée ont une progression plus lente des symptômes et une meilleure qualité de vie.

Céréales et fruits

Les préférences pour les légumes et les fruits étaient associées à une diminution du risque de maladie de Parkinson et à aucune association significative avec le PVS. Ces résultats concordent avec les conclusions d’études antérieures selon lesquelles une consommation élevée de fruits et légumes est liée à un risque plus faible de maladie de Parkinson. Une consommation élevée de fruits et légumes pourrait expliquer une partie des effets protecteurs de la maladie de Parkinson observés dans le régime méditerranéen.

Les préférences liées aux céréales étaient associées à une réduction du fer cérébral. Ce résultat est surprenant étant donné que les céréales sont un véhicule courant pour l’enrichissement en fer. Similairement les grains de céréales peuvent contenir entre 50 et 80 % de glucides en poids, on pourrait donc penser que ce type de nourriture a un effet défavorable sur la maladie de Parkinson. Mais, les céréales et les produits laitiers, généralement consommés avec les céréales, sont riches en inhibiteurs de l'absorption du fer comme l'acide phytique et le calcium, qui réduisent la biodisponibilité du fer en chélatant et en cloîtrant le fer dans le tube digestif. L'interprétation actuelle des auteurs est que les niveaux plus faibles de fer dans le cerveau observés chez les individus préférant les céréales sont dus aux inhibiteurs de l'absorption du fer présents dans ces repas et que l'association qui est observée se produit malgré l'enrichissement en fer des céréales et non à cause de celui-ci.

Conclusion

En conclusion, c'est une étude intéressante, qui montre bien la complexité de la biologie humaine et que les maladies ne se réduisent pas à la carence ou l'excès de quelque molécule, contrairement à ce que le biologie moléculaire laisse entendre.

For a patient, participating in a clinical trial is complicated to organize, in addition, the drugs tested are very rarely effective in the field of neurodegenerative diseases. However, it seems that there are unexpected benefits to volunteering for a clinical trial.

Clinical trials in neurodegenerative diseases are often disappointing, there are probably many reasons for that situation. A core aspect of clinical trials is that the population who received the treatment should be representative of the general population. For logistic reasons, biotechs that have few employees have to subcontract clinical trials. Principal investigators and subcontractors have every reason to select patients who present a textbook-like disease.

Suspecting that the clinical trial population is not representative of real-life patients, an international team wanted to characterize the progression of Parkinson's disease using real-world data to guide the design of clinical trials and identify subpopulations.

The increasing availability of real-world data, and recent advances in natural language processing, particularly large language models, allow for an easier and more granular comparison of populations than before.

This study includes two research populations and two populations derived from real-world data.

The research populations are the Harvard Biomarkers Study (935 patients), which is a longitudinal biomarker cohort study with structured in-person study visits, and finally Fox Insights (36,660 patients), a research study based on the Michael J. Fox Foundation online self-survey.

The real-world cohorts are Optum Integrated Claims electronic health records (157,475 patients), representing large-scale linked medical and claims data and de-identified data from Mass General Brigham (Mass General Brigham, 22,949 patients), a University Hospital.

Structured, anonymized data from Mass General Brigham's electronic health records is augmented using natural language processing with a large language model to extract measures of Parkinson's disease progression. This extraction process is manually validated to verify accuracy.

Motor and cognitive progression scores change more rapidly in the Mass General Brigham than in the Harvard Biomarkers Study (median survival to H&Y scale: 5.6 years versus more than 10 years); median decline to mini-exam of mental status 0.28 versus 0.11. In real-world populations, patients are diagnosed more than eleven years later! After diagnosis, in real-world cohorts, treatment with Parkinson's drugs is initiated 2.3 years later on average than for patients in clinical trials.

This study provides a detailed characterization of Parkinson's disease progression in various populations. It delineates systemic discrepancies between patient populations enrolled in research settings and real-world patients. The study shows systematic differences and potential directional biases between research and real-world datasets. Patients in research populations are diagnosed much earlier, start levodopa and other Parkinson's medications earlier, and show slower changes in clinical scales of motor and cognitive progression. Real-world-based populations are diagnosed at older ages, start medications later than research cohorts, and experience more rapid changes in clinical scales.

These discrepancies are likely due to a combination of selection bias, but exact attribution of causes is difficult using existing data. This study emphasizes the need to diligently consider potential biases when planning a clinical trial.

This post is about an interesting hypothesis. Hypotheses abound, yet few a convincing.

Half of patients with Alzheimer's disease, Parkinson's disease, or ALS have insulin resistance. Obesity and diabetes have been linked to neurodegenerative diseases like multiple sclerosis (MS), Alzheimer's (AD), and Parkinson's (PD). This means the cells of their body cannot let the glucose enter them. Glucose is the main energy source as it is converted into ATP. Glucose is for short-term (day) energy needs. Another source of energy is lipids (fat). Lipids are even more dense than glucose energy-wise.

The body needs an enormous amount of energy. With all the lipids in the body of a healthy person, you could charge two Tesla cars! The brain (a part of the CNS) needs 20% of all energy intake.

A new paper argues that cells shift their metabolism from glucose to lipids under stressors. It tells that one notable distinction between glucose and lipid metabolism is in the quantity of oxygen required to generate each ATP molecule. Lipid metabolism needs two times more oxygen than glucose metabolism. The result is two times more damaging ROS (a by-product of metabolism). Studies have shown that oxidative stress and endoplasmic reticulum stress are correlated and can lead to protein misfolding (Abramov et al., 2020). Accumulation of misfolded proteins causes cellular damage and mitochondrial dysfunction and is associated with a range of neurodegenerative diseases, including ALS (misfolded SOD1, TDP-43, C9orf72) (McAlary et al., 2020), Parkinson's disease (misfolded α-synuclein) and Alzheimer disease (misfolded Aβ and Tau) (Abramov et al., 2020).

It explains also the accumulation of iron in patients' brains: To transport oxygen the blood cells need iron, and as the glucose in the blood is not absorbed in cells, it induces a change in microbiota.

It's also well known that SCFAs (including butyrate) have a positive effect on neurodegenerative diseases by their action on microbiota. SCFAs help to restore glucose as the preferred energy substrate. Authors say there are other means to restore glucose as the main source of energy.

What to think about this paper? First, some authors belong to a biotech so we can expect they want to promote their drug: Mitometin. Second, this is a review, this is not even a pre-clinical study, yet some of the authors were involved in pre-clinical studies on this topic. Other groups have written on this topic. What to make of this? Acetyl-CoA carboxylase might be of interest as they produce malonyl-CoA which inhibits the CPT1 gene that regulates lipid metabolism. B7 vitamin is known to convert acetyl-CoA to malonyl-CoA for fatty acid synthesis.

Now you have an opportunity to fast-track the discovery of drugs in some neuro-degenerative diseases.

AstraZeneca, the pharmaceutical company, proposes a challenge in the area of nucleotide repeat expansion disorders, which includes ALS (Charcot/Gehrig) disease, but also Huntington's disease, etc...

Typically you have to be a startup or an academic with a plan to launch a startup because your solution must be translated into practice within a 12–18-month timeframe.

I am willing to provide reasonable help if you hesitate. This will be mostly in terms of shaping your proposal. I believe that AstraZeneca, like other large companies, is not interested in unproven, hypothetical ideas. On the contrary, IMO they search for people with energy and time (and intellectual right) to give blood to ideas where there is a consensus but where nobody cared to develop it in the pre-clinical stage.

I guess also AstraZeneca would prefer a simple implementation, instead of a complex one. So for example, a small molecule proposal would be preferred to a genetic therapy. A compound of two or three existing drugs to an untested drug. You get the idea.

Good luck!

Jean-Pierre Le Rouzic You will find the link to email me at the bottom of this page.

Unfortunately, after decades of research and hundreds of unsuccessful phase III clinical trials, it's clear that the pharmacological industry and a cohort of academic laboratories are unable to create drugs that slow significantly the progression of neurodegenerative diseases.

Some courageous scientists interrogate basic hypotheses or design longer, more complex better clinical trials. For example, Alzheimer's disease can't seriously be attributed to any molecular dysfunction, as it would mean that a lot of cerebral functions would be affected, not only memory issues, and anyway, memory issues in Alzheimer's are much more complex than described in textbooks: They did not simply vanish: The patient looks to be living today in the context of the past. Sometimes the patient can discuss simultaneously at two levels: In the context of the past (when they were infants) and in the context of today.

Others are currently busy breaking the thermometer. If the clinical diagnosis makes it impossible to validate current clinical trials, then change the way success is defined: Abandon clinical criteria and use molecular criteria. They did it recently for Alzheimer's disease and now they propose it for Parkinson's disease..

The immediate consequence will be a flurry of successful clinical trials, even if patients get no improvements, as they did for Aducanumab.

There will also be false positives, people will be diagnosed sick because of the presence of a molecule but without any clinical signs.

Alpha-synuclein, the protein implicated in Parkinson's disease, is primarily localized in presynaptic terminals of neurons. In particular, it is involved in the regulation of neurotransmitter release, maintenance of synaptic integrity, and plasticity of synapses and, consequently, cognitive processes. But it's not simply the presence of a protein that is important, much more important is the place and time a protein changes, either in location, composition, or in shape. Those changes are caused by a chemical signal for example: phosphorylation. Phosphorylation events are omnipresent in our bodies. For example, phosphorylation of muscles' myosin, enables the contraction of muscle filaments. Phosphorylation is catalyzed by enzymes known as kinases which regulate various cellular functions by adding phosphate groups to specific target molecules. The phosphorylation-dephosphorylation cycle is dynamic and reversible, providing cells with a rapid and precise means of responding to external cues. Importantly, the balance between kinase and phosphatase activity (enzymes that remove phosphate groups) determines the overall phosphorylation status of a cell and influences its physiological state.

The phosphorylation of alpha-synuclein is associated with the formation of aggregates like Lewy bodies, contributing to the neurodegenerative process characteristic of Parkinson's disease and Lewy body dementia. It is not known if the phosphorylation of alpha-synuclein is causative of Parkinson's disease and Lewy body dementia.

This addition of a phosphate group is done at specific sites in the molecules, in the case of alpha-synuclein, it is done at a site called Ser129. Previous research suggested that abnormal accumulation of alpha-synuclein, when phosphorylated at Ser129, contributes to the formation of Lewy bodies—protein aggregates commonly found in the brains of individuals with Parkinson's. These Lewy bodies are associated with the degeneration of dopaminergic neurons, a hallmark of Parkinson's disease.

A new publication by Leonardo Parra-Rivas, Subhojit Roy, and colleagues at the University of California, San Diego, investigates the phosphorylation of alpha-synuclein (α-syn) at the Ser129 site and its implications in Parkinson's disease (PD) and related synucleinopathies.

Their study challenges the view that Ser129 phosphorylation directly causes toxicity and proposes a physiologic role in synaptic function. Indeed this has consequences Their new research somehow has consequences for common statements that abnormal accumulation of phosphorylated alpha-synuclein, contributes to the formation of Lewy bodies—protein.

Almost all pathologically aggregated α-syn in Lewy bodies is phosphorylated at Ser129. Antibodies to Ser129 α-syn are sensitive markers for neuropathologic diagnosis in synucleinopathies. Studies often use Ser129 phosphorylation as a surrogate marker for pathology. Intrigually, inhibitors against Polo-like kinase 2 (PLK2), responsible for α-syn phosphorylation, were explored as a PD drug target. However, PLK2 over-expression surprisingly suppressed neurodegeneration in vivo, challenging expectations. This hints that the physiological role of phosphorylated α-syn at Ser129 is misunderstood.

For the authors of this new publication, under normal physiological conditions, only a small fraction (∼4%) of α-syn is phosphorylated at Ser129. Despite its low frequency, Ser129P is produced during normal metabolism, raising questions about its exclusive pathological role. A recent study suggests that increasing neuronal activity augments Ser129 phosphorylation, implying that it may be linked to an increase in cognitive works and that the role of α-synuclein protein may be to regulate excessive neuronal firing. This suggests that α-syn might have a role in healthy brains, which had not previously been investigated. The researchers give an interesting example: "In hindsight, we hadn't been looking at synuclein phosphorylation the right way, take, for instance, the circuits in the olfactory bulb, which according to our data has high levels of phosphorylated α-synuclein. The nose never stops smelling, so it needs to be active all the time. One hypothesis is that synuclein phosphorylation may have evolved as a safety mechanism to protect neuronal circuits that need to be hyperactive."

The authors systematically examined α-syn Ser129 phosphorylation using various assays, in vivo studies, cell-free assays, mass spectrometry, electron microscopy, and dynamic simulations. when α-synuclein is phosphorylated, its structure changes in a way that promotes interactions with other proteins in healthy brains. The scientists propose a model where Ser129 phosphorylation induces conformational changes at the α-syn C terminus, facilitating its association with functional interacting partners and eliciting α-syn function.

Conclusion: The study challenges the view that Ser129 phosphorylation directly causes toxicity and proposes a physiologic role in synaptic function. Yet it is done on cultured cells and in mouse brain tissue, so those findings are far from being confirmed in humans. As we all know you can find contradictory studies in scientific literature and only clinical trials are credible (when authorities do not bypass their findings).